daratumumab (Darzalex)

From Aaushi
Jump to navigation Jump to search

Indications

* daratumumab combined with bortezomib, melphalan, & prednisone reduces risk of disease progression or death in patients with stem-cell ineligible multiple myeloma than same regimen without daratumumab[2]

Contraindications

Adverse effects

other

Laboratory

Mechanism of action

More general terms

Additional terms

References

  1. FDA News Release. November 16, 2015 FDA approves Darzalex for patients with previously treated multiple myeloma http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472875.htm
  2. 2.0 2.1 2.2 Mateos MV, Dimopoulos MA, Cavo M et al Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. Dec 12, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29231133 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1714678
  3. 3.0 3.1 3.2 Minerd J with Expert Critique from Short NJ Tips for Using Daratumumab. What clinicians should know about this new option for multiple myeloma. MedPage Today. ASCO Reading Room. March 14, 2018 https://www.medpagetoday.com/reading-room/asco/hematologic-malignancies/71748
  4. 4.0 4.1 Rixecker TM, Leppervpm, Mang S et al Daratumumab for a Patient With Refractory Antineutrophil Cytoplasmatic Antibody- Associated Vasculitis. JAMA Intern Med. Published online April 10, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37036724 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2803783